CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 126 enrolled
Drug / intervention
Fluoxetine + outpatient cognitive behavioral therapy +2 moredrug
Likely dose
Fluoxetine + outpatient cognitive behavioral therapy 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00061113
NCT00061113Phase 4Completed
CompareCT.gov

Substance Dependent Teens - Impact of Treating Depression Study 1

National Institute on Drug Abuse (NIDA)·interventional·Posted May 22, 2003·Updated Jan 12, 2017

In Brief

A Phase 4 clinical trial evaluating Fluoxetine + outpatient cognitive behavioral therapy, fluoxetine, and 1 other intervention for Alcohol-Related Disorders and 2 related conditions. Completed, enrolled 126 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate the impact of treating depression on substance dependent teens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol-Related Disorders, Marijuana Abuse, Substance-Related Disorders
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 22, 2003
Enrollment StartFeb 1, 2001
Primary CompletionAug 1, 2006
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 23.1 years ago

Interventions

Fluoxetine + outpatient cognitive behavioral therapydrug

single fixed morning dose 20 mg X 15 weeks

fluoxetinedrug

20mg, QD x 16 weeks

placebo + CBTdrug

single fixed morning dose X 16 weeks